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Mucin 5B (MUC5B) has an essential role in mucociliary clear-
ance that protects the pulmonary airways. Accordingly, knowl-
edge of MUC5B structure and its interactions with itself and
other proteins is critical to better understand airway mucus
biology and improve the management of lung diseases such as
asthma, cystic fibrosis, and chronic obstructive pulmonary dis-
ease (COPD). The role of an N-terminal multimerization
domain in the supramolecular organization of MUC5B has been
previously described, but less is known about its C-terminal
dimerization domain. Here, using cryogenic electron micros-
copy (cryo-EM) and small-angle X-ray scattering (SAXS) analy-
ses of recombinant disulfide-linked dimeric MUC5B dimeriza-
tion domain we identified an asymmetric, elongated twisted
structure, with a double globular base. We found that the
dimerization domain is more resistant to disruption than the
multimerization domain suggesting the twisted structure of
the dimerization domain confers additional stability to MUC5B
polymers. Size-exclusion chromatography-multiangle light
scattering (SEC-MALS), SPR-based biophysical analyses and
microscale thermophoresis of the dimerization domain dis-
closed no further assembly, but did reveal reversible, calcium-
dependent interactions between the dimerization and multim-
erization domains that were most active at acidic pH, suggesting
that these domains have a role in MUC5B intragranular organi-
zation. In summary, our results suggest a role for the C-terminal
dimerization domain of MUC5B in compaction of mucin chains
during granular packaging via interactions with the N-terminal
multimerization domain. Our findings further suggest that the
less stable multimerization domain provides a potential target
for mucin depolymerization to remove mucus plugs in COPD
and other lung pathologies.
Polymeric mucins are the major structural component of
mucus; a hydrogel that plays a pivotal role in protecting muco-
sal surfaces. In healthy airways, mucus in conjunction with cilia,
protect the airway epithelium from inhaled pathogens, parti-
cles, and toxins (1, 2). The polymeric mucins confer the correct
rheological properties for the gel to facilitate removal of these
inhaled components by mucociliary clearance (MCC).4 How-
ever, during airway diseases such as asthma, cystic fibrosis (CF),
and chronic obstructive pulmonary fibrosis (COPD), mucus
concentration is increased which results in an increase in vis-
coelasticity. The abnormal mucus impairs effective MCC, gen-
erating an environment that harbors pathogenic microbes
(3–5).
MUC5B and MUC5AC are the major polymeric mucins in
respiratory tract mucus (6 –9). The focus of this study is
MUC5B, which is essential for mucociliary clearance of the
lung (10, 11). MUC5B is a large (2–50 MDa), multidomain gel-
forming glycoprotein that shares high sequence homology
with the cysteine-rich domains of von Willebrand factor
(vWF) at its N- and C-terminal regions (12, 13). MUC5B
consists of an N-terminal region composed of vWF-like
D1-D2-D-D3 domains, a central proline-threonine-serine-
rich mucin domain interspersed with cysteine-rich (Cys)
domains, and C-terminal region composed of vWF-like D4-B-
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C-CK domains (14). The N- and C-terminal regions are important
for disulfide bond-mediated polymer assembly.
MUC5B biosynthesis is a multistep process involving CK-do-
main disulfide-mediated C-terminal dimerization in the endo-
plasmic reticulum, and extensive O-glycosylation of the central
mucin domain followed by D3-domain disulfide-mediated N-ter-
minal multimerization in the Golgi apparatus (15–19). The assem-
bled, linear MUC5B polymer is packaged in a compact and cross-
linked form inside secretory granules, via noncovalent interactions
between N-terminal dimerization domains controlled by calcium
ions and acidic pH (19–21). Post-secretion, uncoupling of these
mucin-mucin interactions allows transition to an expanded linear
chain that is critical for formation of a flowing mucus gel that
facilitates lung protection by MCC (1). The supramolecular orga-
nization of MUC5B within mucus is not completely described,
although recent studies have shown that submucosal gland-de-
rived MUC5B forms assemblies of the linear mucin strands,
termed bundles (22).
Compromised MCC is a feature of muco-obstructive disease
and there are multiple mechanisms proposed to generate the
pathogenic mucus associated with asthma, CF, and COPD;
important contributors include concentration of mucin, defec-
tive mucin expansion, and covalent cross-linking of the
secreted mucin network (20, 23–27). Understanding how air-
way obstruction can be reversed is crucial to tackling mucus
accumulation in the airways. Therefore, elucidating the molec-
ular details of mucin structure, assembly, packaging, and post-
secretory expansion is critical in the development of mucolytic
therapies that can directly target the mucin polymers that
underpin the adherent mucus plugs/plaques. Although the
structure and roles of the MUC5B N-terminal multimerization
domain in MUC5B assembly and intragranular packaging have
been described (19, 21) the roles of other protein-rich regions of
MUC5B in airway mucus biology have not been elucidated.
Therefore, we have focused on elucidating the structure and
functional roles of the C-terminal dimerization domain of
MUC5B in polymer stability and intragranular packaging.
Here, using recombinant protein (D4-B-C-CK), we describe the
detailed structure of the C-terminal dimerization domain of
MUC5B using single particle cryo-electron microscopy (cryo-EM)
and small-angle X-ray scattering (SAXS). We demonstrate that
the C-terminal dimerization domain of MUC5B has similar
structure to that of the related glycoprotein, vWF (28, 29). More-
over, we show that the C-terminal dimerization domain confers
extra stability on the MUC5B polymer compared with the N-ter-
minal dimerization domain. Finally, we have gained new insight
into the molecular details of MUC5B packaging in secretory gran-
ules by using recombinant C-terminal protein to investigate the
effect of calcium and pH on (a) homotypic interaction between
C-terminal dimerization domain and (b) heterotypic interaction
with recombinant N-terminal multimerization domain.
Results
Expression and characterization of MUC5B C-terminal
dimerization domain
To investigate the structure and further define the role of
the C-terminal dimerization domain of MUC5B, we stably
expressed a C-terminal construct of MUC5B (CT5B), con-
sisting of D4-B-C-CK domains (Fig. 1A). We also expressed
the previously published N-terminal dimerization domain
of MUC5B (NT5B protein) consisting of D1-D2-D-D3
domains (19). The expressed proteins were purified from
conditioned 293-EBNA medium using a combination of
nickel affinity, size exclusion, and anion exchange chroma-
tography. The reduced (R) and nonreduced (NR) proteins
were analyzed by SDS-PAGE (Fig. 1B) and showed that
CT5B was expressed mainly as a disulfide-linked dimer with
a small proportion of monomer. The molecular mass for the
CT5B dimer (245 kDa) and monomer (147 kDa) was
determined by size exclusion chromatography multi-angle
static light scattering (SEC-MALS) (Fig. 1C).
Structural analysis of MUC5B dimerization domain
We investigated the structure of dimeric CT5B using
cryo-EM and SAXS (Fig. 2 and Figs. S1 and S2). 2D classifica-
tion of CT5B showed an elongated shape consisting of a glob-
ular base connected to an extended stalk region (Fig. 3C and Fig.
S1B). There appeared to be flexibility between the globular base
and the stalk as visualized in the 2D classes (Fig. S1B). As CT5B
is a dimer, the data were processed using either C1 or C2 sym-
metry. The C1 structure refined to a resolution of 9.3 Å, where
the twist in the stalk was clearly visible (Fig. 2A), and the C2
structure refined to a resolution of 8.9 Å where the base bene-
fitted from the application of 2-fold symmetry, but the flexible
stalk structure deteriorated when symmetry was applied (Fig.
2B). Therefore, the stalk was subtracted from the C2 refined
structure and locally refined resulting in a gain in resolution to
7.5 Å (Fig. S1C and Fig. 3). A composite map of the refined C2
base and the C1 stalk is shown in Fig. 2C, where CT5B is a “T”
shaped dimeric molecule with dimensions 21  18  5 nm
(height  width  depth).
Analysis of the SAXS data confirmed the flexible nature of
CT5B, with the normalized Kratky plot indicating a biphasic
system with both globular and elongated regions connected
by limited flexibility (Fig. 2D). Based on the similarity to the
vWF structure and crystal structure of the vWFD domain
(28, 29), it was clear that the D4 region was located in the
globular base structure. A homology model of the D4 region
was therefore generated, which readily docked into the sym-
metric base (Fig. 3). The D4 domains form a butterfly shape
with the termini connecting through the central axis. The
CT5B region has 13 predicted N-glycans per monomer so
some areas where the EM density is not fully occupied by
protein structure may reflect the locations of N-glycans,
which could also add flexibility to the structure (Fig. S3B). A
resolution of 7.5 Å was achieved despite the heterogeneity
contributed by complex N-glycosylation and conformational
flexibility through the stalk region.
The B-C-CK domains form the stalk structure. It was
apparent from the 2D class averages (Fig. 3C and Fig. S1B)
and 3D reconstruction (Fig. 2, A and C) that the two mole-
cules within the stalk region twist around each other. This
may increase the interface and the number of domain-do-
main interactions between the monomers in the stalk region,
potentially increasing the stability of this C-terminal region
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(Fig. 3). To determine whether the structure of the C-termi-
nal dimerization domain is pH regulated, we analyzed the
CT5B dimer by size exclusion chromatography at different
pH values (Fig. S4). Results showed no evidence of a change
in CT5B structure at different pH values. Taken together,
our data suggest that the twist in the stalk of the molecule,
Figure 1. Expression of recombinant MUC5B protein domains. A, schematic showing the domain structure of N- and C-terminal constructs of MUC5B. The
constructs were composed of a N-terminal His6 tag (gray square) coupled to the MUC5B domains, NT5B (D1-D2-D-D3) and CT5B (D4-B-C-CK). B, N- and
C-terminal constructs, reduced (R) with 10 mM DTT and nonreduced (NR), were analyzed by SDS-PAGE, and stained with InstantBlue. Gel splicing occurred at
the position indicated by the dashed line, the data came from the same gel. C, recombinant CT5B in 0.2 M NaCl, pH 7.4, was analyzed by SEC-MALS and the
representative graph shows the differential refractive index. The chromatograph showed two peaks corresponding to dimer (peak II) and monomer (peak I).
Experiments were repeated at least 3 times.
Figure 2. Structural analysis of MUC5B multimerization domain. Cryo-EM maps of CT5B refined using either C1 (A) or C2 (B) symmetry shown with a rotation
through 90 degrees. C, a composite map of CT5B showing the stalk from the C1 model (yellow) and the C2 base (blue) from an independent subtracted
refinement. D, normalized Kratky plot calculated from the SAXS data of CT5B showing a biphasic profile indicating that CT5B has rigid and flexible regions.
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which represents the B-C domains, could be a feature that
provides enhanced stability to the CT5B dimer.
Stability of the dimerization and multimerization domains
MUC5B forms linear polymers via disulfide-linked N-N and
C-C–terminal interactions. We compared the relative stability
of the expressed protein representing the N-terminal multim-
erization domain of MUC5B (NT5B) (Fig. 1B) (19) with CT5B
by using limited proteolysis and partial reduction approaches.
The NT5B and CT5B proteins were treated with 1 mM DTT on
ice (partial reduction; Fig. 4, A and B) or with 1 g/ml of trypsin
at room temperature (partial proteolysis; Fig. 4, C and D) and
samples collected at different time points were analyzed by
SDS-PAGE. Dimer and monomer bands are indicated by
arrows and trypsin inhibitor (50 kDa) is indicated by a dashed
arrow. Results showed that CT5B dimer was resistant to limited
proteolysis and partial reduction, maintaining a dimer through-
out the time course of the experiment (Fig. 4, B and D). In
contrast, NT5B dimer was sensitive to both treatments, being
reduced to monomer in the presence of DTT after 0.5 min
(Fig. 4A) and lower molecular weight species by the action of
trypsin within 1 min (Fig. 4C).
To assess whether this differential stability demonstrated
with the N- and C-terminal recombinant proteins was observed
with native polymers, we analyzed purified MUC5B following
proteolysis. SEC-MALS analysis showed that proteolysis
caused a reduction in the average molecular mass of MUC5B
from 6.8 to 3.5 MDa (Fig. 5A). Western blot analysis before and
after proteolysis was performed and blots were probed for D3
domain (5BVIII) in the N terminus, and B domain (CC1) in the
C terminus, and total glycoprotein was determined by PAS
stain (Fig. 5B). Results for the unreduced samples showed
70% loss of N-terminal antibody signal following proteolysis,
whereas the C-terminal antibody signal was only decreased by
15% (Fig. 5C). A similar trend was observed for the samples
that were reduced prior to electrophoresis. These data are con-
sistent with results following trypsin digestion of the recombi-
nant MUC5B proteins (Fig. 4, C and D) and demonstrate that in
native MUC5B polymers the C-terminal dimerization domain
is more stable than the N-terminal multimerization domain.
Effect of calcium and pH on the dimerization domain of
MUC5B
We next investigated the potential role of CT5B in MUC5B
intragranular packaging. Prior to secretion, linear disulfide-
stabilized MUC5B polymers are condensed and packaged
within secretory granules that have an acidic pH and high cal-
cium content (1, 19). We previously demonstrated that the dis-
ulfide-linked dimeric N-terminal multimerization domains of
MUC5B were noncovalently assembled into tetramers through
calcium-mediated cross-links, active at acidic pH (pH 5– 6)
(21). This interaction is proposed to change the organization of
the linear polymeric chains and aid their ordered packaging
inside secretory granules (19). To determine whether calcium
and acidic pH could cause noncovalent interactions between
the recombinant C-terminal multimerization domain; dimeric
CT5B was incubated in the presence or absence of calcium (5
mM) at pH 7.4 or 6 and analyzed by SEC-MALS (Fig. S5A).
Results in the presence of EGTA at pH 7.4 and 6 (Fig. 5A, i and
ii) showed a peak of dimer (peak II) and monomer (peak I). In
the presence of calcium at pH 7.4, 6, or 5, the profiles of CT5B
were similar to the data for EGTA and showed that calcium and
pH did not facilitate noncovalent interactions between CT5B
(Fig. S5A, iii–vi). These results were also confirmed using ana-
lytical ultracentrifugation, which showed monomer (I) and
dimer (II) peaks with similar sedimentation profiles for CT5B
under all conditions studied (Fig. S5B, i–iii). These data show
that unlike the N-terminal multimerization domain, the C-ter-
minal dimerization domain of MUC5B does not form homo-
typic calcium or pH-dependent multimers and therefore, does
not have the same role as the N-terminal multimerization
region in the organized packaging of MUC5B.
Effect of calcium and pH on the interaction between the
dimerization and multimerization domains of MUC5B
Although the presence of calcium and acidic pH did not
engender homotypic interaction between CT5B, we hypothe-
sized that the C-terminal multimerization domains of MUC5B
may interact with N-terminal dimerization domains during
packaging to further facilitate the organization of the mucin
polymer inside the secretory granule. Using surface plasmon
Figure 3. Structural overview of C-terminal MUC5B. A, the composite map (from Fig. 2C) is shown with docked models of each domain. A dimer of the D4
domain fits within the base, with the monomers colored red and blue. In the stalk, the B-C-CK domains are fitted twisting along the stalk axis, with each
monomer colored orange and blue. B, a surface rendered representation of the docked models shown in A with each monomer chain color coded either red or
blue. C, a representative 2D class of CT5B showing this twist along the length of the stalk.
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resonance (SPR), the interaction of immobilized dimeric CT5B
with 50 nM dimeric NT5B was analyzed in the presence of 5 mM
CaCl2 over a range of pH (Fig. 6A). This pH scouting assay
showed that there was some low background binding between
NT5B and CT5B in the presence of calcium at pH 7.4. Binding
was shown to increase as a function of decreasing pH, the most
binding was at pH  6.2, and binding was abolished following
EDTA treatment. Single cycle kinetic assays were performed
with increasing concentrations of NT5B (5-40 nM) flowed over
immobilized CT5B in the presence of 5 mM CaCl2 at pH 6 and
7.4 (Fig. 6B, solid black line and dashed line, respectively). Anal-
ysis showed a strong binding interaction between NT5B and
CT5B at pH 6, with a KD value of 1  0.04 nM. At pH 7.4,
NT5B flowed over immobilized CT5B with 5 mM CaCl2 and
produced some binding with a KD value in a similar range (3
nM), however, the binding response was 5-fold lower; suggest-
ing the same binding affinity, but a much lower amount of
NT5B bound.
We investigated the heterotypic binding further by perform-
ing in solution analysis of the interaction between NT5B (fluo-
rescently labeled) and CT5B (serially diluted) using microscale
thermophoresis (MST). The data were analyzed using a KD
model of fit using the NT Affinity Analysis software (Fig. 6, C
and D). The results confirmed that NT5B and CT5B interact in
calcium at pH 6, with a KD of 3  1.4 nM (Fig. 6D, circles), which
was comparable with the result obtained from SPR. The results
also showed an interaction at pH 7.4 with a similar binding
affinity (KD 7.4  1.5 nM; Fig. 6C). Importantly, there was no
interaction detected between NT5B and CT5B in the presence
of EGTA at either pH (Fig. 6, C and D, triangles). These results
establish that MUC5B dimerization and multimerization
domains form reversible pH-sensitive and calcium-dependent
intermolecular associations between polymeric mucins.
Discussion
Determining the nature of polymeric mucin chain interac-
tions during packaging into secretory granules and their subse-
quent uncoupling post-secretion is critical to understanding
the mechanisms that control mucus gel formation in health and
disease. Abnormal mucus gel properties may arise due to mucin
chains not fully expanding upon secretion, resulting in altered
molecular structure. Indeed, airway mucins with aberrant mac-
romolecular structure are a feature of hyper-concentrated
mucus that obstructs the CF airways (23). We have previously
described a role for the N-terminal multimerization domain of
MUC5B in forming noncovalent, reversible calcium-depend-
ent tetramers that are involved in the organization of the mucin
chains within the secretory granule (19, 21). Here we have
extended understanding of MUC5B intragranular packaging by
describing a role for the MUC5B C-terminal dimerization
domain.
During packaging of MUC5B within secretory granules, the
mucin chains are organized around protein nodes formed
from pH and calcium-dependent, noncovalent, reversible,
homotypic interactions between N-terminal multimerization
domains (19, 21). In marked contrast, we demonstrate that the
C-terminal dimerization domain of MUC5B does not form
homotypic multimers in the presence of calcium at acidic pH,
suggesting it has a different function in intragranular packag-
ing. Indeed, using SPR and MST we demonstrated the potential
Figure 4. Stability of the dimerization and multimerization domains of recombinant MUC5B. A, recombinant NT5B and B, CT5B were partially reduced by
incubation with 1 mM DTT on ice for 0.5 to 180 min. Samples without DTT were incubated for 0 and 180 min. C, recombinant NT5B and D, CT5B were subjected
to limited proteolysis with 1 g/ml of trypsin for 1 to 240 min at room temperature. Samples without trypsin were incubated for 0 min. The bands visible at
approximately 50 and 20 kDa represent the trypsin inhibitor and trypsin, respectively. Dimer (D) and monomer (M) of NT5B and CT5B are indicated by arrows,
and trypsin inhibitor is indicated by a dashed arrow. The experiments were repeated 3 times.
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for reversible, calcium-dependent heterotypic interactions
between the dimerization and multimerization domains of
MUC5B most active at acidic pH. We propose that these het-
erotypic interactions aid further compaction of MUC5B during
packaging, adding an additional level of organization of the
mucin polymers inside the secretory granule (Fig. 7). Further
work is required to investigate whether there are any other pro-
tein-protein interactions, perhaps with the internal Cys
domains of MUC5B (7 in total), that contribute to the full
mechanism of packaging and subsequent unfurling of mucins
into mucus.
Although the structure of the N-terminal multimerization
domain of MUC5B has been described (19, 21), there is little
information on the C-terminal dimerization domain. To
address the gap in our knowledge, the structure of the C-termi-
nal dimerization domain of MUC5B was determined using
SAXS and cryo-EM analysis, and was identified as an anisotro-
pic, extended structure with globular domains. The stalk sec-
tion of the structure contained a twist, which we interpret as a
key structural feature that is likely to contribute to stabilization
of the dimerization domain. The related C-terminal region of
vWF has a similar shape, described as an extended dimeric stem
with bouquet structure (28). However, there are certain differ-
ences between MUC5B and vWF C-terminal structures. In
vWF, there is no evidence of a twist in the stem-like structure,
although interactions have been hypothesized between each
pair of tandem C domains (30). Also, at neutral pH encountered
during secretion, the vWF stem-like structure unzips, remain-
Figure 5. Stability of the dimerization and multimerization domains of polymeric MUC5B. MUC5B was incubated with 1 g/ml of trypsin for 0 and 24 h
at 37 °C. A, samples were analyzed by SEC-MALS on a Shodex OHpak SB-806 M HQ column. The molecular mass of peaks is indicated (MDa). This experiment was
repeated twice. B, samples (reduced (R) and nonreduced (NR)) were analyzed on an agarose gel and transferred to nitrocellulose, then probed with MAN-5BVIII
(D3 domain) or CC1 (B domain) antisera or PAS stained. C, nonreduced bands were quantified, then MAN-5BVIII and CC1 signals were divided by PAS stain signal
(total glycoprotein) and expressed as a percentage compared with the 0 h sample (dashed line). Error bars represent the S.D. This experiment was repeated 3
times.
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ing disulfide-bonded at the CK domain (28). Our results
showed that the C-terminal structure of MUC5B was not sub-
ject to pH-dependent changes, and maintained a stable confor-
mation, potentially aided by the noncovalent bonded, twisted
structure of the C domain. These differences between the two
molecules may be attributed to the presence of a larger number
of B and C domains in the C terminus of vWF (D4-B-B-B-C-C-
CK) compared with MUC5B (30 –33) and the distinct roles of
the two molecules. The resolution of our cryo-EM data are
most likely limited by the flexibility of the protein, as shown in
the 2D classes (Fig. S1B) and by the normalized Kratky plot (Fig.
2D), and the large proportion of heterogeneity as a result of
glycosylation across the molecule (18).
This study is the first to describe the structure of the MUC5B
mucin dimerization domain and it may form a model for other
members of the polymeric mucin family. The C-terminal of
MUC5B shares some sequence homology with the other
polymeric mucins MUC2 and MUC5AC (34 –37). However,
MUC2 and MUC5AC contain a GDPH autocatalytic cleavage
sequence in their D4 domain that is absent in MUC5B (the
equivalent sequence is GGSH). The GDPH site is cleaved at
acidic pH for MUC2, and neutral to acidic pH for MUC5AC,
producing reactive ends that may be involved in forming self-
interactions, interactions with other molecules and/or the epi-
thelial cell surface (38, 39). There is no evidence in the literature
for C-terminal cleavage in MUC5B. Therefore, there are poten-
tial differences in the stability of the C-terminal dimerization
domains of MUC2 and MUC5AC compared with MUC5B,
which may affect their function.
On comparing the stability of the N- and C-terminal regions
of MUC5B, results showed that the C-terminal dimerization
domain was more resistant to degradation than the N-terminal
multimerization domain, this was seen with both recombinant
proteins and the native MUC5B polymer. We have shown here
that the central stalk of the dimerization domain has a twisted
structure, whereas the multimerization domain has a more
open conformation in a boomerang-like shape (19). Thus, the
differences in structure correlate well with the differences
noted in their stability. These findings provide new insight into
the structure and stability of the MUC5B polymer, which may
benefit future therapeutic development to alleviate pathology
associated with airway mucus obstruction. Indeed, there are
already reports of mucolytic agents that directly target the
integrity of airway mucin polymers to improve airway clear-
ance by reducing the viscosity of abnormal mucus (40 –42). The
determination of the differential structure and stability of the
critical regions involved in MUC5B polymer assembly offers
potential to design more targeted mucoactive agents. In this
case, the multimerization domains of MUC5B appear to pro-
vide a better target, than the more stable dimerization domains,
for production of a mucolytic agent to breakdown mucin poly-
Figure 6. Analysis of heterotypic interaction of MUC5B dimerization and multimerization domains. A, a pH scan of 50 nM NT5B in different pH buffers in
the presence of 5 mM CaCl2, flowed over CT5B immobilized to a chip and analyzed using SPR. There was some background binding at pH 7.4, but strong binding
occurred between NT5B and CT5B at pH  6.2. This experiment was performed once with triplicate samples. B, single cycle kinetic analysis with increasing
concentrations of NT5B in 5 mM CaCl2 (0, 5, 10, 15, 20, and 40 nM) at pH 6 (black line) or pH 7.4 (dashed line). C and D, serially diluted recombinant CT5B protein
was mixed with an equal volume of fluorescently labeled NT5B recombinant protein, and interactions were measured by fluorescence using MST. Samples
were prepared in HBS buffer containing 0.05% Tween 20 and either 5 mM CaCl2 (circles) or 5 mM EGTA (triangles) at pH 7.4 (C) or 6 (D). Error bars represent the
mean  S.E. Experiments in B–D were repeated at least twice.
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mers and thereby reduce mucus accumulation and improve
lung function.
In summary, this study has elucidated a potentially new role
for the C-terminal dimerization domain of MUC5B in aiding
compaction of mucin chains during granular packaging, via
heterotypic interactions with the N-terminal multimerization
domains. Results have determined a detailed structure for the
dimerization domain of MUC5B, which has shown some simi-
larity with the related vWF C-terminal structure. The struc-
tural data have highlighted a central twist in the structure of the
dimerization domain, and we propose that this feature contrib-
utes to enhanced stability of this region of the MUC5B polymer.
Experimental procedures
Expression and purification of recombinant human MUC5B
protein domains
MUC5B (UniProtKB accession number Q9HC84) C-termi-
nal construct consisting of D4-B-C-CK (CT5B; residues 4955–
5762) (12) was created with an N-terminal His6 tag using the
mammalian episomal expression vector pCEP-His in 293-
EBNA cells (19, 43, 44) (Fig. 1A). The N-terminal construct
(NT5B consisting of D1-D2-D-D3) has been described previ-
ously (19) (Fig. 1A). A Superose 6 10/300 GL column was used
for size fractionation. Protein identity and purity were con-
firmed by tandem MS. Samples, with and without treatment
with 10 mM for 4 min at 95 °C, were analyzed by SDS-PAGE
using 4 –12% BisTris gels (Life Technologies) and stained with
InstantBlue (Expedeon).
SEC-MALS
For determination of molecular mass by SEC-MALS analysis,
recombinant proteins were applied to a Superose 6 10/300 GL
column and MUC5B was applied to a Shodex OHpak SB-806 M
HQ column, in 0.2 M NaCl, 0.05 M EDTA, 0.05% sodium azide.
For experiments in the presence of calcium and EGTA, recom-
binant CT5B protein was incubated overnight at 4 °C in 5 mM
CaCl2 or 5 mM EGTA at pH 7.4 or 6 in 25 mM HEPES, 150 mM
NaCl, before applying to a Superose 6 10/300 GL column at
room temperature. For samples at pH 6 and 5, the HEPES was
replaced with 25 mM MES. Column eluents passed through an
in-line Helios 18-angle laser photometer and a T-rEX refrac-
tometer with QELS dynamic light scattering attachment
(Wyatt Technology). Analysis was performed using ASTRA
version 6 software.
Analytical ultracentrifugation
Recombinant CT5B protein was incubated in the presence of
5 mM CaCl2 overnight at 4 °C in either HEPES or MES buffer (25
mM HEPES, 150 mM NaCl, pH 7.4, or 25 mM MES, 150 mM
NaCl, pH 6 or pH 5). Samples were analyzed using velocity
experiments on an Optima XL-A ultracentrifuge (Beckman
Instruments), as previously described (19). The sedimentation
coefficients were determined using SedFit version 13.0b (45).
Cryo-EM
Grid prep, regular grids—Quantifoil R1.2/1.3 holey carbon
grids were cleaned in 2 chloroform soaks on filter paper in a
glass Petri dish and then glow discharged for 2 min at 25 mA. 3
l of purified CT5B at 0.25 mg/ml was applied to the grids and
blotted for 8 –10 s at 22 °C in a Vitrobot Mark IV (Thermo
Fisher Scientific), before plunge freezing in liquid ethane.
Data acquisition—Cryo-EM data were collected on a Titan
Krios electron microscope operating at 300 kV equipped with a
K2 Summit direct detector (Gatan) and a FEI Volta phase plate
(Thermo Fisher Scientific) at the Electron Bio-Imaging Centre
(eBIC) (Didcot, UK). EPU (Thermo Fisher Scientific) was used
to automate the collection of 1441 movies, comprising of 40
frames, 10 s exposures, and a total dose of 40 e Å2 were
recorded on the detector in counting mode at a calibrated mag-
nification of 93,000 corresponding to a magnified pixel size of
1.043 Å. Defocus was maintained at 0.5 m as suggested pre-
viously (46).
Data processing—The recorded movies were processed in
cryoSPARC v2.8 (47, 48). Movies were aligned using local
patch-based motion correction. CTF estimation of the aligned
movie stacks was carried out using the local patch-based CTF
estimation. Images were then excluded based on motion dis-
tance, resolution fit, defocus, and phase shift resulting in 1093
images. Several hand-picked particles were submitted to 2D
classification and used for template-based picking over the
entire data set. 231,589 particles were extracted after per parti-
cle motion correction in a 500 pixel box. Particles were submit-
ted to two rounds of 2D classification and resulted in 16,590
particles. These particles were used to generate an ab initio
Figure 7. Model for MUC5B intracellular assembly and packaging. In the
endoplasmic reticulum, MUC5B forms homotypic disulfide-linked dimers via
its C-terminal dimerization domains (blue circles). The dimer is transported to
the Golgi where it undergoes O-glycosylation prior to linear polymer forma-
tion via disulfide linkage between N-terminal multimerization domains (red
circles). A reduction in pH and an increase in free calcium concentration occur
across the secretory pathway. This results in noncovalent, calcium-mediated
interactions between N termini, which appear as proteinaceous nodes, and
aid organization of MUC5B for intragranular packaging. The new findings in
this paper extend this model and establish that the C-terminal dimerization
domains have the potential to interact with the multimerization domains at
acidic pH in the presence of calcium, which may aid further compaction of the
MUC5B molecule for intragranular packaging. The order of assembly of these
N- and C-terminal containing nodes has yet to be elucidated. Uncoupling of
these noncovalent interactions in mucus is critical for the transition to an
expanded linear chains underpinning normal flowing mucus that can be
transported by MCC to keep the lung free from infection. Addition of agents
to mucus that displace calcium from mucins has been shown to normalize
mucin conformation and decrease mucus viscoelasticity and improve MCC
(64, 65).
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model for further refinement. Refinement was carried out using
C1 and C2 symmetries resulting in structures with resolutions
of 10.0 and 9.4 Å, respectively. Heterogeneous refinement was
then applied to each result with modest differences between the
classes. The particles from the best classes were then used to
re-refine the structure resulting in lower resolution structures.
Non-uniform refinement was then used to refine the C1 and C2
refined models resulting in a resolution of 9.3 and 8.9 Å, respec-
tively. Particle subtraction was then employed to enhance the
resolution of each of the base or stalk regions using masks
around the base and stalk. Further refinement of both sub-
tracted symmetry models were completed yielding a base with a
resolution of 7.5 Å. The stalk, in the absence of the base, was
refined but resulted in a much lower resolution map.
Model generation
The sequence of CT5B (residues 4955–5762) was submitted
to the HHpred server (49 –51) through the new MPI Bioinfor-
matics Toolkit online portal (52). HHpred was able to identify
structures in the PBD (53) with homology equating to 97% of
the CT5B sequence (784 residues of 807). The homologous
structures showed high probability with values greater that
95%. The corresponding PDBs (Table 1) and sequence were
then submitted to Modeller (54) though the online portal.
The resulting models were downloaded and manually placed
into the cryo-EM density map using Chimera (55). As the
C-CK domains contain an intramolecular disulfide bond in
the cysteine knot, a homology model of the C-CK domain
was generated in SWISS-MODEL (56), which generated a
homology model based on chain B of the second biological
assembly of PDB 5BPU (57); the C-CK homology model was
produced with an intramolecular disulfide bond. Glycans
were identified on the full sequence using NetNGlyc server
(www.cbs.dtu.dk/services/NetNGlyc/).5
SAXS
SAXS intensity data, I(q) versus q (q  4. sin 2), of CT5B
were collected using SEC-SAXS on beamline B21 (Diamond
Light Source, UK). 50 l of BMPER was loaded onto a Superdex
200 Increase 3.2/300 column (GE Healthcare) at 0.075 ml/min.
SAXS data were collected at 3-s intervals on an Eiger X 4M
detector (Dectris) at a distance of 2.7 m and wavelength of
0.95 Å.
Data were reduced using in-house software. Subtractions of
the SEC-SAXS data were completed for each frame across the
elution peak and the radius of gyration (Rg) and the integral of
intensity ratio to background were plotted. The data were
scaled, merged, and averaged for each frame with a consistently
similar Rg. All further processing and analysis of data were car-
ried out using ScÅtter (www.bioisis.net/scatter)5 (66).
Partial reduction and limited proteolysis of recombinant
MUC5B proteins
For partial reduction experiments, NT5B and CT5B proteins
were incubated with 1 mM DTT on ice between 0.5 and 180 min.
At each time point, 2.5 mM iodoacetamide was added and incu-
bated for 15 min in the dark at room temperature. For limited
proteolysis, NT5B and CT5B proteins were incubated with 1 g
of sequencing-grade trypsin (Promega) at room temperature
for 1 to 240 min. At each time point, 1 l of trypsin neutralizing
solution (Lonza) was added to stop the reaction. Samples were
analyzed by SDS-PAGE using 4 –12% BisTris gels (Life Tech-
nologies), staining with InstantBlue (Expedeon).
Partial proteolysis of native MUC5B
MUC5B was purified from A549MUC5Bm (A549 cell line in
which MUC5AC was knocked down by gene editing) cell-con-
ditioned medium using cesium chloride isopycnic centrifuga-
tion in 0.1 M NaCl, as previously described (58). The MUC5B
was further purified on a Sepharose CL2B size exclusion col-
umn. Partial proteolysis of purified MUC5B was achieved by
incubation with 1 g of trypsin at 37 °C for 0 and 24 h. Trypsin
neutralizing solution (1 l; Lonza) was added to samples to stop
the reaction. Samples (reduced (R) and nonreduced (NR)) were
equally loaded in triplicate and analyzed on 0.7% (w/v) agarose
gels in 40 mM Tris acetate, 1 mM EDTA, pH 8.0, containing 0.1%
SDS, for 16 h. Following electrophoresis, gels with unreduced
samples were incubated with 10 mM DTT in 4 SSC, pH 8.0, for
15 min. MUC5B was transferred to nitrocellulose membrane by
vacuum blotting at 45 millibars for 1.5 h. The membrane was
cut into strips and either probed with polyclonal MAN-5BVIII
antiserum (19), which detects the N-terminal D3 domain and
CC1 antiserum, which detects C-terminal B domain, at 1:2000
dilution. A secondary IRDye 800CW antibody (LI-COR Bio-
sciences) was used for detection and blots were analyzed on the
LI-COR Odyssey CLx and quantified using Image Studio Lite
v5.2 software (LI-COR Biosciences). The final strip was stained
using PAS as previously described (59), and bands were imaged
on a Bio-Rad ChemiDocTM MP and quantified using Image Lab
v5.2 software (Bio-Rad Laboratories). The nonreduced bands
were quantified, and a ratio of the signal was determined for
5BVIII and CC1 relative to PAS signal.
SPR
To investigate interactions between NT5B and CT5B pro-
teins, a Biacore T200 biosensor with Biacore Control software
was used (GE Healthcare). Initially 25 g/ml of CT5B diluted in
50 mM sodium acetate, pH 5.5, was immobilized onto a CM5
sensor chip by amine coupling using 1-ethyl-3(3-dimethyl-
aminopropyl)-carbodiimide hydrochloride, N-hydroxysuccin-
imide, and ethanolamine-HCl (GE Healthcare). The immobi-
lized CT5B gave 3400 response units. To perform a pH scan
experiment, purified NT5B protein (50 nM) was injected over
5 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
Table 1
Modeling the domains of CT5B based on structural homology
The table shows the percentage identity between domains in CT5B and the corre-
sponding structures from the PDB.
Target
length Probability PDB code (chain) Citation
%
483 100 6N29 (B) 60
103 95.3 2MHQ (A) 61
85 98.3 6FWN (A) 62
113 98.8 2KD3 (A) 63
MUC5B structure, stability, and interactions
J. Biol. Chem. (2019) 294(45) 17105–17116 17113
the immobilized CT5B in varying pH buffers containing 5 mM
CaCl2 and 0.05% Tween 20 for 120 s at a flow rate of 30 l/min
and dissociation time of 60 s. The CM5 sensor chip was regen-
erated after each sample application with 10 mM EDTA, pH 7.4,
at a flow rate of 30 l/min for 30 s and stabilization of 1 min
after regeneration. For single cycle kinetic analysis, 0, 5, 10, 15,
20, and 40 nM NT5B analyte was flowed over the immobilized
CT5B in HBS containing 5 mM CaCl2 and 0.05% Tween 20, at
pH 6 or 7.4. Curves were fitted using 1:1 Langmuir association/
dissociation model (Biacore Evaluation 4.1 software; GE
Healthcare) to obtain kinetic values of binding affinity.
MST
Purified NT5B protein in 25 mM HEPES, 150 mM NaCl, pH
7.4, was fluorescently labeled using the MonolithTM NT protein
labeling kit RED-NHS (Amine Reactive) dye, following the
manufacturers’ instructions (NanoTemper Technologies). All
stock protein samples were centrifuged for 10 min prior to set-
ting up the experiment. The labeled NT5B protein was diluted
to 2.5 nM final concentration, in the appropriate buffer for each
experiment (25 mM HEPES, 150 mM NaCl, 0.05% Tween 20,
with either 5 mM CaCl2 or 5 mM EGTA, at pH 7.4 or 6). The
nonlabeled recombinant CT5B protein was serially diluted 1:1
in the same buffer (starting concentration of 6 M) and an equal
volume of the labeled protein was mixed with each dilution.
The samples were loaded onto MonolithTM NT.115 Standard
Treated Capillaries (NanoTemper Technologies) and thermo-
phoresis was measured using a MonolithTM NT.115PICO
instrument (NanoTemper Technologies) with NT Control
software version 1.0.1 at room temperature with 5 s/30 s/5 s
laser off/on/off times, respectively, and 15% LED power and
40% IR-laser (MST) power. Experiments were carried out in
triplicate and data from three independently pipetted measure-
ments were analyzed using NT Affinity Analysis software ver-
sion 2.0.2, using the KD model of fit.
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